共 22 条
[1]
Chang M.Y., Ong A.C.M., Autosomal dominant polycystic kidney disease: Recent advances in pathogenesis and treatment, Nephron Physiol, 108, pp. 1-7, (2008)
[2]
Torres V.E., Meijer E., Bae K.T., Et al., Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 study, Am J Kidney Dis, 57, 5, pp. 692-699, (2011)
[3]
Walz G., Budde K., Mannaa M., Et al., Everolimus in patients with autosomal dominant polycystic kidney disease, N Engl J Med, 363, 9, pp. 830-840, (2010)
[4]
Serra A.L., Poster D., Kistler A.D., Et al., Sirolimus and kidney growth in autosomal dominant polycystic kidney disease, N Engl J Med, 363, 9, pp. 820-829, (2010)
[5]
Hogan M.C., Masyuk T.V., Page L.J., Et al., Randomized clinical trial of longacting somatostatin for autosomal dominant polycystic kidney and liver disease, J Am Soc Nephrol, 21, 6, pp. 1052-1061, (2010)
[6]
Julian B.A., Wittke S., Haubitz M., Et al., Urinary biomarkers of IgA nephropathy and other IgA-associated renal diseases, World J Urol, 25, (2007)
[7]
Mason S.B., Lai X., Bacallao R.L., Et al., The biomarker enriched proteome of autosomal dominant polycystic kidney disease cyst fluid, Proteomics Clin Appl, 3, pp. 1247-1250, (2009)
[8]
Kistler A.D., Mischak H., Poster D., Et al., Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease, Kidney Int, 76, pp. 89-96, (2009)
[9]
Nagaraj N., Mann M., Quantitative analysis of the intra- And inter- individual variability of the normal urinary proteome, J Proteome Res, 10, 2, pp. 637-645, (2011)
[10]
Marimuthu A., O'Meally R.N., Chaerkady R., Et al., A comprehensive map of the human urinary proteome, J Proteome Res, 10, 6, pp. 2734-2743, (2011)